Taysha Gene Therapies, Inc. - Common Stock (TSHA)
1.3200
+0.0600 (4.76%)
NASDAQ · Last Trade: Apr 2nd, 5:59 PM EDT
Detailed Quote
Previous Close | 1.260 |
---|---|
Open | 1.260 |
Bid | 1.250 |
Ask | 1.310 |
Day's Range | 1.240 - 1.360 |
52 Week Range | 1.170 - 4.320 |
Volume | 1,649,867 |
Market Cap | 85.09M |
PE Ratio (TTM) | -3.667 |
EPS (TTM) | -0.4 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 2,356,494 |
About Taysha Gene Therapies, Inc. - Common Stock (TSHA)
Taysha Gene Therapies Inc is a biotechnology company focused on developing and delivering innovative gene therapies for the treatment of various neurological diseases, particularly genetic disorders that impact the central nervous system. By leveraging advanced technologies, Taysha aims to create transformative therapies that address the underlying causes of these diseases, providing hope for patients with limited treatment options. The company's research and development efforts emphasize collaboration with leading academic institutions and experts to advance its pipeline of gene therapy products toward clinical application. Read More
News & Press Releases
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via Chartmill · March 31, 2025
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · March 31, 2025

Via Benzinga · January 6, 2025

Via Benzinga · November 15, 2024
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · March 31, 2025

Via Benzinga · November 14, 2024

Via Benzinga · November 14, 2024

Via Benzinga · August 12, 2024

Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks.
Via MarketBeat · November 14, 2024

Via Benzinga · November 14, 2024

Via Benzinga · November 12, 2024

Via Benzinga · November 12, 2024

Via Benzinga · November 12, 2024

Via Benzinga · November 12, 2024

TSHA stock results show that Taysha Gene Therapies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 12, 2024

Taysha Gene Therapies stock is down on Wednesday after the company announced a proposed public offering for TSHA shares.
Via InvestorPlace · June 26, 2024

It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning!
Via InvestorPlace · June 26, 2024

Via Benzinga · June 26, 2024

Via Benzinga · June 19, 2024